| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22025 |
| Drug |
Tepotinib |
| Brand |
Tepmetko® |
| Indication |
For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
| Rapid review commissioned |
22/04/2022 |
| Rapid review completed |
30/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tepotinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
13/09/2022 |
| Full submission received from Applicant |
10/01/2023 |
| Preliminary review sent to Applicant |
23/05/2023 |
| NCPE assessment re-commenced |
22/06/2023 |
